Search

Author/Creator Carlo-Stella, C.

1. 192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study. (December 2022)

Authors:
Di Giacomo, A.M.; Santangelo, F.; Amato, G.; E. Simonetti, ; Graham, J.; Lahn, M.; van der Veen, L.; Hammett, T.; Pickering, C.A.; Durini, M.; Ziyang, T.; Lakshmikanth, T.; Brodin, P.; Occhipinti, M.; Simonelli, M.; Carlo-Stella, C.; Santoro, A.; Spiliopoulou, P.; Evans, T.R.J.; Maio, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). (23rd June 2022)

Authors:
Piccione, E. C.; Belousov, A.; Hamidi, H.; Carlo-Stella, C.; Dickinson, M.; Morschhauser, F.; Lundberg, L.; Humphrey, K.; Tracy, S.; Hutchings, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1096
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5). (23rd June 2022)

Authors:
Hamadani, M.; Linhares, Y.; Gandhi, M. D.; Chung, M.; Adamis, H.; Ungar, D.; Carlo-Stella, C.; Kingsley, E.; Depaus, J.; Snauwaert, S.; Kwiatek, M.; López-Jiménez, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1989
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022)

Authors:
Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
74
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. (23rd June 2022)

Authors:
Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
81
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL). (23rd June 2022)

Authors:
Carlo-Stella, C.; Ansell, S.; Zinzani, P. L; Radford, J.; Maddocks, K.; Pinto, A.; Collins, G. P.; Bachanova, V.; Bartlett, N.; Bence-Bruckler, I.; Hamadani, M.; Kline, J.; Mayer, J.; Savage, K. J.; Advani, R.; Caimi, P.; Casasnovas, R.-O.; Feldman, T.; Hess, B.; Bastos-Oreiro, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS. (23rd June 2022)

Authors:
Dickinson, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Wróbel, T.; Offner, F.; Trněný, M.; Wu, S.-J.; Cartron, G.; Hertzberg, M.; Sureda, A.; Perez-Callejo, D.; Lundberg, L.; Relf, J.; Clark, E.; Humphrey, K.; Hutchings, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
121
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA. (23rd June 2022)

Authors:
Pirosa, M. C.; Bruscaggin, A.; Terzi di Bergamo, L.; Salehi, M.; Pini, K.; Spina, V.; Bocchetta, S.; Condoluci, A.; Forestieri, G.; Piffaretti, D.; Marques De Almeida, J.; Annunziata, S.; Bergesio, F.; Borsatti, E.; Bulian, P.; Chauvie, S.; Marco, C.; Martina, D. T.; Bernhard, G.; Kurlapski, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
126
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search